丙卡巴肼、洛莫司汀和长春新碱联合治疗复发性高级别胶质瘤的有效性和安全性比较研究：系统评价与荟萃分析方案

A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis.

作者信息

Cai Yang, Jiang Yu-Gang, Wang Ming, Jiang Zhuo-Hang, Tan Zhi-Gang

机构信息

Department of Neurosurgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.

出版信息

Medicine (Baltimore). 2020 Sep 18;99(38):e22238. doi: 10.1097/MD.0000000000022238.

DOI:10.1097/MD.0000000000022238

PMID:32957367

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7505370/

Abstract

BACKGROUND

Systematic evaluation of the effectiveness and safety of combined procarbazine, lomustine, and vincristine for treating recurrent high-grade glioma.

METHODS

Electronic databases including PubMed, MEDLINE, EMBASE, Cochrane Library Central Register of Controlled Trials, WanFang, and China National Knowledge Infrastructure (CNKI) were used to search for studies related to the utilization of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma. Literature screening, extraction of data, and evaluation of high standard studies were conducted by 2 independent researchers. The robustness and strength of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic methodology for recurrent high-grade glioma was assessed based on the odds ratio (OR), mean differences (MDs), and 95% confidence interval (CI). RevMan 5.3 software was used for carrying out the statistical analysis.

RESULTS

These results obtained in this study will be published in a peer-reviewed journal.

CONCLUSION

Evidently, the conclusion of this study will provide an assessment on whether combined procarbazine, lomustine, and vincristine provides an effective and safe form of treatment for recurrent high-grade glioma.

SYSTEMATIC REVIEW REGISTRATION NUMBER

INPLASY202080078.

摘要

背景

对丙卡巴肼、洛莫司汀和长春新碱联合治疗复发性高级别胶质瘤的有效性和安全性进行系统评价。

方法

使用包括PubMed、MEDLINE、EMBASE、Cochrane图书馆临床试验中央注册库、万方和中国知网（CNKI）在内的电子数据库，检索有关丙卡巴肼、洛莫司汀和长春新碱联合治疗复发性高级别胶质瘤的研究。由2名独立研究人员进行文献筛选、数据提取和高标准研究评估。基于比值比（OR）、平均差（MDs）和95%置信区间（CI）评估丙卡巴肼、洛莫司汀和长春新碱联合治疗复发性高级别胶质瘤作为一种治疗方法的有效性和安全性的稳健性和强度。使用RevMan 5.3软件进行统计分析。